Division of Genome Stability Research, National Cancer Center Research Institute, Japan.
Mol Aspects Med. 2013 Dec;34(6):1202-16. doi: 10.1016/j.mam.2013.05.003. Epub 2013 May 25.
Cancer develops through diverse genetic, epigenetic and other changes, so-called 'multi-step carcinogenesis', and each cancer harbors different alterations and properties. Here in this article we review how poly(ADP-ribosyl)ation is involved in multi-step and diverse pathways of carcinogenesis. Involvement of poly- and mono-ADP-ribosylation in carcinogenesis has been studied at molecular and cellular levels, and further by animal models and human genetic approaches. PolyADP-ribosylation acts in DNA damage repair response and maintenance mechanisms of genomic stability. Several DNA repair pathways, including base-excision repair and double strand break repair pathways, involve PARP and PARG functions. These care-taker functions of poly(ADP-ribosyl)ation suggest that polyADP-ribosyation may mainly act in a tumor suppressive manner because genomic instability caused by defective DNA repair response could serve as a driving force for tumor progression, leading to invasion, metastasis and relapse of cancer. On the other hand, the new concept of 'synthetic lethality by PARP inhibition' suggests the significance of PARP activities for survival of cancer cells that harbor defects in DNA repair. Accumulating evidence has revealed that some PARP family molecules are involved in various signaling cascades other than DNA repair, including epigenetic and transcriptional regulations, inflammation/immune response and epithelial-mesenchymal transition, suggesting that poly(ADP-ribosyl)ation both promotes and suppresses carcinogenic processes depending on the conditions. Expanding understanding of poly(ADP-ribosyl)ation suggests that strategies to achieve cancer prevention targeting poly(ADP-ribosyl)ation for genome protection against life-long exposure to environmental carcinogens and endogenous carcinogenic stimuli.
癌症是通过多种遗传、表观遗传和其他变化(即所谓的“多步骤致癌作用”)发展而来的,每种癌症都具有不同的改变和特性。在本文中,我们回顾了聚(ADP-核糖)化如何参与致癌作用的多步骤和多样化途径。聚ADP-核糖化和单ADP-核糖化在致癌作用中的参与已在分子和细胞水平上进行了研究,并进一步通过动物模型和人类遗传方法进行了研究。聚ADP-核糖化在 DNA 损伤修复反应和基因组稳定性的维持机制中发挥作用。几种 DNA 修复途径,包括碱基切除修复和双链断裂修复途径,都涉及 PARP 和 PARG 的功能。这些聚(ADP-核糖)化的“管家”功能表明,聚 ADP-核糖化主要起肿瘤抑制作用,因为 DNA 修复反应缺陷引起的基因组不稳定性可能成为肿瘤进展的驱动力,导致癌症的侵袭、转移和复发。另一方面,“PARP 抑制的合成致死性”这一新概念表明,对于在 DNA 修复中存在缺陷的癌细胞来说,PARP 活性对其生存具有重要意义。越来越多的证据表明,一些 PARP 家族分子参与了除 DNA 修复以外的各种信号级联反应,包括表观遗传和转录调控、炎症/免疫反应和上皮-间充质转化,这表明聚(ADP-核糖)化根据条件既促进又抑制致癌过程。对聚(ADP-核糖)化的深入了解表明,针对聚(ADP-核糖)化的策略可以实现癌症预防,从而保护基因组免受终生暴露于环境致癌物和内源性致癌刺激物的影响。